Role of NOD1 polymorphism in susceptibility and clinical progression of rheumatoid arthritis.
OBJECTIVE
One of the disease hallmarks of RA is progressive cartilage and bone destruction in the joints. The exact mechanism underlying this disease process is largely unknown. Nod1, an intracellular pattern recognition receptor expressed by the innate immune system, has been previously shown to display anti-inflammatory effects in experimental arthritis. Furthermore, an insertion/deletion polymorphism in NOD1 has been demonstrated to modulate cytokine responses of immune cells. In this study, the effect of the insertion/deletion polymorphism in NOD1 on RA susceptibility and severity was assessed.


METHODS
Ex vivo stimulation of primary immune cells and osteoclasts with microbial triggers was performed to measure cytokine responses and osteoclast-specific gene expression in relation to the NOD1 genotype. In total, 1047 RA patients from two centres were genotyped for the NOD1 polymorphism and compared with 431 healthy controls. Clinical scores of joint inflammation and destruction were correlated with the NOD1 genotype.


RESULTS
Functional analysis revealed increased production of pro-inflammatory cytokines in cells from individuals bearing the NOD1 +32656 insertion allele. Furthermore, osteoclast bone resorption activity was elevated, as reflected by increased expression of the lysosomal protease cathepsin K. However, the insertion allele of the NOD1 +32656 polymorphism was not associated with either susceptibility to, or clinical parameters of, inflammation or bone destruction in RA patients.


CONCLUSIONS
These findings demonstrate that the NOD1 polymorphism modulates pro-inflammatory cytokine responses induced through Toll-like receptor or Nod-like receptor ligands. Nevertheless, these effects of genetic variation in NOD1 appear to be redundant in RA susceptibility and severity.
Department of Medicine, Radboud University Nijmegen Medical Centre, Internal postal code 463, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Theo S
TS
Plantinga
Jaap
J
Fransen
Rachel
R
Knevel
Mihai G
MG
Netea
Jochen
J
Zwerina
Monique M A
MM
Helsen
Jos W M
JW
van der Meer
Piet L
PL
van Riel
Georg
G
Schett
Annette H M
AH
van der Helm-van Mil
Wim B
WB
van den Berg
Leo A B
LA
Joosten
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000235:genetics* / Q000503:physiopathology; D001862:Bone Resorption / Q000235:genetics / Q000503:physiopathology; D016022:Case-Control Studies; D016207:Cytokines / Q000378:metabolism*; D018450:Disease Progression; D005260:Female; D005786:Gene Expression Regulation; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D053474:Nod1 Signaling Adaptor Protein / Q000235:genetics*; D011110:Polymorphism, Genetic; D012016:Reference Values; D018570:Risk Assessment
D016207:Cytokines; C119067:NOD1 protein, human; D053474:Nod1 Signaling Adaptor Protein